WallStreetZenWallStreetZen

NASDAQ: CDXC
Chromadex Corp Stock

$3.40+0.00 (+0%)
Updated Apr 24, 2024
CDXC Price
$3.40
Fair Value Price
-$3.41
Market Cap
$256.05M
52 Week Low
$1.25
52 Week High
$4.65
P/E
-48.57x
P/B
9x
P/S
1.28x
PEG
N/A
Dividend Yield
N/A
Revenue
$83.57M
Earnings
-$4.94M
Gross Margin
60.8%
Operating Margin
-5.91%
Profit Margin
-5.9%
Debt to Equity
0.93
Operating Cash Flow
$7M
Beta
0.93
Next Earnings
May 8, 2024
Ex-Dividend
N/A
Next Dividend
N/A

CDXC Overview

ChromaDex Corporation operates as a bioscience company focusing on healthy aging. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches on nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers, as well as to distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and IMMULINA, a Braun-type lipoproteins, including spirulina extracts and active compounds, which are used to support human immune function. It also offers analytical reference standards and services comprising supply of products to conduct quality control of raw materials and consumer products in dietary supplements, cosmetics, food and beverages, life sciences, and pharmaceutical industries. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. ChromaDex Corporation is headquartered in Los Angeles, California.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how CDXC scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

CDXC ($3.40) is overvalued by 199.61% relative to our estimate of its Fair Value price of -$3.41 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
CDXC ($3.40) is not significantly undervalued (199.61%) relative to our estimate of its Fair Value price of -$3.41 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
CDXC is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more CDXC due diligence checks available for Premium users.

Be the first to know about important CDXC news, forecast changes, insider trades & much more!

CDXC News

Valuation

CDXC fair value

Fair Value of CDXC stock based on Discounted Cash Flow (DCF)
Price
$3.40
Fair Value
-$3.41
Undervalued by
199.61%
CDXC ($3.40) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
CDXC ($3.40) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
CDXC is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

CDXC price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-48.57x
Industry
15.69x
Market
41.27x

CDXC price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
9x
Industry
5.86x
CDXC is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation

CDXC's financial health

Profit margin

Revenue
$21.2M
Net Income
$114.0k
Profit Margin
0.5%
CDXC's Earnings (EBIT) of -$4.94M... subscribe to Premium to read more.
Interest Coverage Financials
CDXC's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$55.0M
Liabilities
$26.5M
Debt to equity
0.93
CDXC's short-term assets ($49.53M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CDXC's short-term assets ($49.53M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CDXC's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
CDXC's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
$649.0k
Investing
-$21.0k
Financing
-$76.0k
CDXC's operating cash flow ($7.12M)... subscribe to Premium to read more.
Debt Coverage Financials

CDXC vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
CDXC$256.05M0.00%-48.57x9.00x
IVVD$253.94M-6.17%-1.18x1.43x
PYXS$258.69M-1.11%-2.41x2.06x
NKTR$253.39M-2.82%-0.95x1.93x
MGX$252.94M-3.98%-0.34x-1.87x

Chromadex Stock FAQ

What is Chromadex's quote symbol?

(NASDAQ: CDXC) Chromadex trades on the NASDAQ under the ticker symbol CDXC. Chromadex stock quotes can also be displayed as NASDAQ: CDXC.

If you're new to stock investing, here's how to buy Chromadex stock.

What is the 52 week high and low for Chromadex (NASDAQ: CDXC)?

(NASDAQ: CDXC) Chromadex's 52-week high was $4.65, and its 52-week low was $1.25. It is currently -26.88% from its 52-week high and 172% from its 52-week low.

How much is Chromadex stock worth today?

(NASDAQ: CDXC) Chromadex currently has 75,309,118 outstanding shares. With Chromadex stock trading at $3.40 per share, the total value of Chromadex stock (market capitalization) is $256.05M.

Chromadex stock was originally listed at a price of $11.70 in Jun 25, 2008. If you had invested in Chromadex stock at $11.70, your return over the last 15 years would have been -70.94%, for an annualized return of -7.91% (not including any dividends or dividend reinvestments).

How much is Chromadex's stock price per share?

(NASDAQ: CDXC) Chromadex stock price per share is $3.40 today (as of Apr 24, 2024).

What is Chromadex's Market Cap?

(NASDAQ: CDXC) Chromadex's market cap is $256.05M, as of Apr 25, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Chromadex's market cap is calculated by multiplying CDXC's current stock price of $3.40 by CDXC's total outstanding shares of 75,309,118.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.